Have a personal or library account? Click to login
S100 Beta Protein as a Marker of Hepatic Encephalopathy: A Breakthrough in Diagnostics or a False Trail? Review of the Literature. Cover

S100 Beta Protein as a Marker of Hepatic Encephalopathy: A Breakthrough in Diagnostics or a False Trail? Review of the Literature.

Open Access
|Apr 2022

Abstract

Hepatic encephalopathy is a dysfunction of the central nervous system caused by chronic and acute liver disease. The dysfunction presents a wide spectrum of symptoms—from the undetectable in a standard clinical examination to hepatic coma—and could be caused by both chronic and acute liver diseases. For many years research has been conducted to find a marker that would allow for the accurate, quick, and possibly inexpensive detection of hepatic encephalopathy. Due to the pathogenesis of hepatic encephalopathy, researchers’ attention is focused on markers of damage to the central nervous system. One of the markers of astrocyte damage, known from research in neurology and neurosurgery, is the protein S100B. Published research results so far are inconclusive, but they allow us to look with optimism at the role of S100B as a marker of minimal hepatic encephalopathy (MHE).

Language: English
Page range: 128 - 131
Submitted on: Aug 17, 2021
Accepted on: Feb 8, 2022
Published on: Apr 6, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Wojciech Pisarek, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.